A Review of Results from Clinical Trials Based on Co-Variants of the R-CHOP Regimen in Untreated Patients with Diffuse Large B-cell Lymphoma
Since 2000, new drugs for treating lymphoproliferative diseases have been introduced in haematology, and their initial indications have been gradually expanded. Some of the so-called „target molecules“ have shown good efficacy when treating some malignant non-Hodgkin lymphomas. The possibility of ac...
Saved in:
| Main Author: | Vanya Slavcheva |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical University - Pleven
2021-12-01
|
| Series: | Journal of Biomedical & Clinical Research |
| Subjects: | |
| Online Access: | https://jbcr.arphahub.com/article/34596/download/pdf/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01) -
Complications and outcomes in diffuse large B‐cell lymphoma with gastric lesions treated with R‐CHOP
by: Tomohiro Kadota, et al.
Published: (2019-03-01) -
Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China
by: Rongqi Li, et al.
Published: (2024-12-01) -
The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients
by: Monika Długosz‐Danecka, et al.
Published: (2019-03-01) -
Personalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results)
by: M. A. Mingalimov, et al.
Published: (2024-12-01)